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ABSTRACT
The androgen receptor (AR) is the main driver of
prostate cancer (PC) development and progression,
and the primary therapeutic target in PC. To date,
two functional ubiquitination sites have been iden-
tified on AR, both located in its C-terminal ligand
binding domain (LBD). Recent reports highlight the
emergence of AR splice variants lacking the LBD that
can arise during disease progression and contribute
to castrate resistance. Here, we report a novel N-
terminal ubiquitination site at lysine 311. Ubiquitina-
tion of this site plays a role in AR stability and is crit-
ical for its transcriptional activity. Inactivation of this
site causes AR to accumulate on chromatin and inac-
tivates its transcriptional function as a consequence
of inability to bind to p300. Additionally, mutation at
lysine 311 affects cellular transcriptome altering the
expression of genes involved in chromatin organiza-
tion, signaling, adhesion, motility, development and
metabolism. Even though this site is present in clini-
cally relevant AR-variants it can only be ubiquitinated
in cells when AR retains LBD suggesting a role for AR
C-terminus in E2/E3 substrate recognition. We report
that as a consequence AR variants lacking the LBD
cannot be ubiquitinated in the cellular environment
and their protein turnover must be regulated via an
alternate pathway.
INTRODUCTION
Prostate cancer (PC) is the most common male malignancy
in developed countries accounting for 15% of newly diag-
nosed male cancer cases in 2012 (World Cancer Research
Fund International). Globally, in 2012 an estimated 307 000
men died from PC with deaths resulting from advanced,
metastatic disease. PC is driven by the androgen receptor
(AR) and tumours will initially respond to androgen depri-
vation therapy (ADT). However, themain clinical challenge
for PC results from the inevitable recurrence of resistant tu-
mours, termed castrate resistant prostate cancer (CRPC) for
which there are no curative treatments and prognosis is ex-
tremely poor. Recently developed second generation anti-
androgens are characterized by a response rate of only 50%
highlighting the need for new targeted therapies (1). The
AR remains a crucial driver in CRPC, which results in com-
mon therapy-induced amplification and over-expression of
full-length (FL) and (alternatively spliced/truncated) AR
variants (AR-V), AR mutations and increased expression
of AR-regulated genes including PSA. Interestingly, an in-
crease in AR mRNA/protein level is the only consistently
observed molecular change in CRPC (2). The AR is a
ligand-inducible transcription factor that regulates genes
involved in prostate growth and transformation (3). Fol-
lowing androgen binding, cytoplasmic AR is phosphory-
lated promoting conformational change resulting in dimer-
ization, chaperone protein dissociation and nuclear translo-
cation. Nuclear AR binds androgen-responsive genes and
activates cellular transcription. We and others have demon-
strated numerous post-translational modifications of AR
that regulate its transcriptional output (4). The intricate bal-
ance between positive and negative AR co-regulators is also
modulated by components of the ubiquitin–proteasome
system.
Ubiquitination is a reversible covalent process that re-
sults in an attachment of a ubiquitin molecule to specific
substrates that regulates multiple cellular processes, includ-
ing protein degradation (5). Ubiquitin attachment is medi-
ated by sequential activating (E1), conjugating (E2) and lig-
ase (E3) enzymes. Ubiquitin contains seven acceptor lysine
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residues (K) which enable poly-ubiquitin chain formation
(6) and one intrinsic Met1 residue that enables linear ubiq-
uitin chain formation (7). The position of the lysine residue
within ubiquitin that is used for ubiquitin chain branching
dictates the fate of the substrate. For example, K48 poly-
ubiquitin chains primarily target proteins for proteasomal
degradation whilst K63 chains primarily mediate cellular
processes, including transcription factor activity, protein–
protein interaction and DNA repair (8). Ubiquitin can be
removed from target proteins by deubiquitinating (DUB)
enzymes (9). Dysregulation of the ubiquitin–proteasome
pathway occurs in PC pathogenesis and multiple AR part-
ners are components of the ubiquitin–proteasome degrada-
tion system. Ligand binding promotes AR ubiquitination
and destruction suggesting that AR turnover and transcrip-
tional activity are coupled (10).
Currently, two AR ubiquitination sites have been iden-
tified at K845 and K847, both in the C-terminal ligand
binding domain (LBD) of AR (11). Several E3 ligases have
been implicated in AR biology with AR ubiquitination
commonly controlling its protein stability. MDM2 was the
first E3 found to ubiquitinate AR with AR phosphory-
lation being a prerequisite for this process which conse-
quently leads to AR protein degradation (12). In the ab-
sence of this phosphorylation AR is ubiquitinated by CHIP
instead (13). SPOP was also implicated in AR destruc-
tion following recognition of an S/T-containing degron and
commonly identified PC-linked SPOP mutants fail to bind
AR to promote its destruction (14,15). Similarly, most con-
stitutively active AR variants (AR-V) lacking the ligand
binding domain which are linked to CRPC are not de-
graded by SPOP. Alternatively, AR ubiquitination can reg-
ulate receptor activity, RNF6 poly-ubiquitinates AR with
K6/K27 linked chains enhancing AR transcriptional activ-
ity through co-activator recruitment. Consequently RNF6
is overexpressed in CRPC and promotes growth under
androgen-depleted conditions (11). These AR modifica-
tions can be reversed by DUB enzymes, including USP26
(16) and USP12 (17,18).
In this manuscript, we report the discovery of a novel N-
terminal domain (NTD) AR ubiquitination site at K311
which regulates both AR protein stability and is also crit-
ical for AR transcriptional activity and binding to p300 in
the presence of androgen.Mutation of this site causes reten-
tion of AR on chromatin and abrogates its activity toward
target genes. When this ubiquitination site is lost transcrip-
tion of over a thousand genes is altered with global changes
to gene expression in chromatin organization, cellular ad-
hesion and motility, signal transduction, development and
cellular metabolism pathways. Additionally, we report that
AR-Vs are not ubiquitinated and hence their activity is nei-
ther regulated through this site nor by theMDM2E3 ligase.
MATERIALS AND METHODS
Antibodies and plasmids
anti-AR (Santa Cruz Biotechnology; N20 and C19 clones),
anti-AR-v7 (Precision Antibodies), anti-H2A.Z (19), anti-
MDM2 (Santa Cruz N20 and SMP14), anti-HA (Santa
Cruz Biotechnology; Y11 clone), anti-FLAG (Sigma), anti-
p53 (Dako), anti--tubulin (Sigma), and anti-ubiquitin
(Santa Cruz Biotechnology) were included in this project.
Plasmids used were pPSA-Luc, pARE3-Luc, pCMV--
gal, pHA-ubiquitin, pMYC-MDM2, pFLAG-His-AR (20)
and pFLAG-His-AR-K311R and pFLAG-V7-ARmutants
generated by in vitro mutagenesis (QuikChange; Strata-
gene). Lentiviral AR careers were prepared as previously
described (21).
Cell culture, transfections, and reporter assays
LNCaP, HEK293T, CWR22Rv1 and COS-7 cells (all pur-
chased from the ATCC) were cultured in RPMI 1640
mediumwith 2mML-glutamine (Invitrogen) supplemented
with 10% (v/v) foetal calf serum (FCS) at 37◦C in 5% CO2.
Transfections were performed using TransIT-LT1 reagent
(MirusBio) following the manufacturer’s instructions.
For luciferase assays, cells were transfected with 50 ng of
pARE3-luc, 50 ng of pCMV--gal and 10 ng of pFLAG-
His-AR and pMYC-MDM2 as required. All reactions were
balanced with pCMV empty vector. Cells were cultured in
steroid-depleted media (SDM) for 48 h followed by sup-
plementation with 10 nM dihydrotestosterone (DHT) for
an additional 24 h. Cells were lysed and incubated in 1×
Promega luciferase assay reagents according to the man-
ufacturer’s instruction, and luciferase counts were estab-
lished and normalized to -galactosidase activity. Results
were normalized to AR expression alone in steroid depleted
conditions.
In vitro ubiquitination assay and mass spectrometry analysis
In vitro ubiquitination assays were performed on purified
N-terminal AR protein (aa 1–518) using a Ubiquitin Con-
jugation Reaction Buffer Kit (SK10) and incorporating the
following enzymes: UBE1 (E-305), UBCH5 (E2–616) and
MDM2 (E3–204) (all purchased from Boston Biochem) ac-
cording to manufacturer’s instructions. Monoubiquitina-
tion assays were performed using a modified ubiquitin lack-
ing the seven lysine ubiquitin acceptor sites, Ub-K0 (UM-
NOK) and polyubiquitination assays performed using wild
type ubiquitin (U-100H). The E3 Ligases CHIP, E6AP and
hPIRH2 were generated via GST purification and in vitro
ubiquitination reactions repeated, reactions utilizing puri-
fied E3 ligases were conducted in the presence of Ubiquitin
aldehyde (Cat U-201) to inhibit any potential deubiquiti-
nase contamination from the E3 purification stage. All re-
actions were activated by ATP and quenched with E1 stop
buffer.
Ubiquitination of N-terminal AR was confirmed via
western blot using anti-AR and anti-ubiquitin antibodies
(as outlined). Samples submitted for proteomic analysis
were resolved via PAGE and stained using a silver stain
II kit (Sigma) according to manufacturer’s instructions or
with coomassie stain. Bands representing monoubiquiti-
nated AR were excised and sent for analysis at Newcastle
University Protein and Proteome Analysis (NUPPA) facil-
ity.
Proteomic analysis
In gel tryptic digest. The excised gel piece was put into a
small volume of NH4HCO3 pH 7.8 and mashed to small
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pieces. The gel pieces were washed with 60% acetonitrile
and washed withNH4HCO3 pH 7.8 prior to reduction in 50
l of 10 mM DTT in 100 mM NH4HCO3 for 1 h at 56◦C.
Subsequently, cysteines were alkylated by adding 50 mM
iodoacetamide in 100mMNH4HCO3 and incubating in the
dark at room temperature for 30 min. Gel pieces were re-
peatedlywashedwith 100mMNH4HCO3 and 50%acetoni-
trile, and dehydrated using 100% acetonitrile. Proteins were
in gel digested with 8 ng of trypsin (Promega) in 50 mM
NH4HCO3, 1 mMCaCl2 and incubated overnight, shaking
in a thermomixer at 37◦C. The digest was stopped through
addition of 5% of TFA. The gel pieces were washed twice
with 60% acetonitrile containing 2% TFA and the washes
were pooled with the aqueous supernatant after the digest.
The volume of the digests was reduced to 10l in a speedvac
and 10% was analysed by LCMSMS.
HPLC conditions. Peptides were concentrated on a
Pepmap C-18 trap column (300 m ID × 5 mm) and sep-
arated on a Pepmap C18 reversed phase column (Dionex,
UK) (3 m particles, 75 m ID × 250 mm) using a linear
gradient over 42 min from 96% A (0.05% formic acid), 4%
B (0.05% formic acid, 80% acetonitrile) to 35% A, 65% B
and a flow rate of 300 nl/min.
Mass spectrometry (MS) conditions. The spray voltage
was 1.6 kV and the temperature of the heated capillary was
set to 200◦C. Survey scans were acquired with enabled lock-
mass from 400–1600 Da at a resolution of 30 000 at m/z
400 after accumulation of 5× 105 ions. The 10 most intense
ions of the survey scan were sequenced concurrently to full
scan acquisition in the orbitrap by collision-induced disso-
ciation (CID, normalized collision energy 35%) in the LTQ.
Maximum filling times were 50 ms for the full scans and 100
ms for the MSMS scans. Precursor ion charge state screen-
ing was enabled and unassigned charge states and singly
charged ions were rejected. Dynamic exclusion was enabled
for 180 s with a maximum dynamic exclusion list of 50 en-
tries and a relative mass window from −0.5 Da to + 1 Da.
Immunoprecipitation (IP). Cells were seeded at 106
cells/90-mm dish, transfected 24 h later with 1 g of each
plasmid as indicated, incubated for 48 h, and lysed di-
rectly into lysis buffer (50 mM Tris, pH 7.5, 150 mMNaCl,
0.2 mM Na3VO4, 1% Nonidet P-40, 1mM PMSF, 1 mM
DTT and 1× protease inhibitors (Roche Applied Science)).
Lysates were incubated with 1 g of antibodies as indicated
for 16 h at 4◦C, and antibodies were pulled down using pro-
tein G-Sepharose beads. For denaturing IPs, cells were sub-
jected to 20 M MG132 proteasomal inhibitor treatment
for the final 16 h followed by collection into lysis buffer
supplemented with 2% SDS and subsequently denatured at
100◦C for 10 min (17). Immunoprecipitants were analyzed
using western blotting.
For chromatin isolation, cells were trypsinized and resus-
pended in 1ml of Buffer A (10 mMHEPES pH 7.9, 10 mM
KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM
DTT and 1 × protease inhibitors cocktail) and incubated
on ice for 10 min. Nuclei were collected by centrifugation at
1200 g for 5 min at 4◦C. Supernatant was used as a cytosolic
fraction and cleaned by centrifugation at 200 g for 5 min at
4◦C. Nuclei were washed in 1 ml of buffer A without glyc-
erol and resuspended in 1ml of buffer B (3 mM EDTA, 0.2
mM EGTA, 1 mM DTT and 1 × protease inhibitor cock-
tail) and incubated on ice for 30 min. Finally, sample was
centrifuged at 1500 g for 5 min at 4◦C and the chromatin
pellet was washed in buffer B seven times followed by dena-
turing immunoprecipitation.
siRNA gene silencing and gene expression analysis. LNCaP
cells were reverse transfected with siRNA using RNAiMax
(Invitrogen) according to the manufacturer’s instructions
and incubated in culture medium for 96 h prior to
cell lysis and analysis by western blotting as described
previously (17) or qPCR. siRNA sequences were as
follows SCR UUCUCCGAACGUGUCACGU[dT][dT];
full length AR CCAUCUUUCUGAAUGUCCU[dTdT];
AR UTR GCCAGCCACACAAACGUUU[dT][dT]. For
RNA sequencing, RNA was extracted using the QIAGEN
RNeasy Plus Mini Kit and all samples were sequenced in
triplicate using Illumina’s total stranded RNA prep kit with
ribozero gold for library preparationwith 100 bp paired end
reads on the Illumina HiSeq 2500 platform, performed by
AROS. Reads were mapped to the reference human genome
hg38 using STAR (22). Per gene raw read counts for each
sample were obtained using HTseq (23). Gene-level dif-
ferential expression analysis was performed using DEseq2
(24). Differentially expressed genes from each comparison
were tested for functionally enriched pathways and gene on-
tology terms using GOseq (25) and Enrichment Map (26).
qPCR. For qPCR RNA was extracted using Trizol
(Invitrogen) according to manufacturer’s instruction, and
quantified using Nanodrop cDNA synthesis using the
oligo dT primers and data analysis was performed as
described previously (18). Briefly, 2 g of RNA was reverse
transcribed with 1ul of MMLV reverse transcriptase, 2 l
of 25nM Oligo-dT and 4 l of 4mM dNTP (Promega).
All qPCR was performed using the relative quantification
method on three independent biological experiments
and each sample was loaded in triplicate. qRT-PCR was
conducted using SYBR®Green on 384-well optical reac-
tion plates with the ABI 7900HT real-time PCR system.
Results were normalized to HPRT1 expression. Primers
were KLK2 F: 5′-AGCATCGAACCAGAGGAGTTCT-3′,
R: 5′-TGGAGGCTCACACACTGAAGA-3′; HPRT1
F: 5′-GAACGTCTTGCTCGAGAGATGTG-3′, R:
5′-CCAGCAGGTCAGCAAAGAATTT-3′; PSA
F: 5′-ACTGCATCAGGAACAAAAGCGT-3′, R:
5′-TGTGGGAAGCTGTGGCTGAC-3′; NDRG1
F: 5′-ACAACCCCCTCTTCAACTACG-3′, R: 5′-
GCCAATAATGCTTTTCAGCCCA-3′.
Chromatin immunoprecipitation (ChIP). ChIPs were
performed as described previously (27). LNCaP cells were
transfected in steroid-depleted medium for 72 h followed by
DHT treatment for 120 min. Data are presented as percent-
age input using the following formula: % input= 100×AE
(amplification efficiency)*(CT adjusted input sample – CT
immunoprecipitated sample). CT refers to cycle threshold.
‘Walking ChiP’ was performed using primers representing
different regions of the human PSA gene enhancer forward
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(F) 5′-GGGGTTTGTGCCACTGGTGAG-3′; reverse
(R) 5′-GGGAGGCAATTCTCCATGGTT-3′; enhancer-
promoter F 5′-TAGAAGACGTGGAAGTAGCTG-
3′; R 5′-AACCTCATGGATCCGGTGTCC-3′; pro-
moter F 5′-TCTAGTTTCTGGTCTCAGAG-3′;
R 5′-TTGCTGTTCTGCAATTACTAG-3′; intron
1 F 5′-CCAAGGACCTCTCTCAATGC-3′; R 5′-
AGGGAATGAGGAGTTCTCAG-3′; exon 3 F
5′-CACACCCGCTCTACGATATGAG-3′; R 5′-
GAGCTCGGCAGGCTCTGACAG-3′; 3′ UTR (un-
translated region) F 5′-TACTGGCCATGCCTGGAGAC-
3′; R 5′-TGGCTCACAGCCTTCTCTAG-3 as pre-
viously described by Lee et al. (28); KLK2 F:
5′-ACCCCTGTTGCTGTTCATCCTG-3′ R: 5′-
CCGCCCTTGCCCTGTTGG-3′; TMPRSS2 F: 5′-
TGGTCCTGGATGATAAAAAAAGTTT-3′, R: 5′-
GACATACGCCCCACAACAGA-3′.
Immunofluorescence. For Immunofluorescence, cells were
cultured in steroid depleted media (SDM) for 72 h followed
by 10 nMDHT treatment for 2 h. Cell were fixed for 20 min
in 4% formaldehyde, permeabilized for 20 min in 0.1% Tri-
ton X-100 in PBS followed by blocking in 1% BSA, staining
and imaging using Zeiss LSM 700 confocal microscope.
RESULTS
In vitro identification of a novel K311 ubiquitination site
Two AR ubiquitination sites (K845/K847) were recently
identified in the C-terminus, both targeted by RNF6 (11).
Previously we demonstrated AR ubiquitination by MDM2
in cell line experiments, but the sites of this ARmodification
were unknown (10). Given that several E3 ligases interact
with AR, it is likely that receptor ubiquitination is catalysed
by multiple enzymes (4). To test this, we established in vitro
ubiquitination assays, incorporating purified N-terminal
AR fragment (aa1-538), E1 (UBE1), E2 (UBCH5) and
various E3 ligase enzymes potentially linked to AR func-
tion to examine specificity of AR ubiquitination. By in-
corporating a modified ubiquitin lacking all seven lysine
ubiquitin acceptor sites (UbK7R), we demonstrated ARN-
terminal mono-ubiquitination by MDM2 (Figure 1A-B),
PIRH2, CHIP and to a lesser extent E6-AP (Figure 1B).
Mass spectrometry analysis of the MDM2 (and PIRH2)-
mediated mono-ubiquitinated N-terminal AR species iden-
tified K311 as an ubiquitin acceptor (Figure 1C), highlight-
ing the AR N-terminus as an E3 target (Figure 1D).
AR K311 is not the sole MDM2-mediated ubiquitination site
MDM2 E3 ligase has been previously implicated in AR
ubiquitination. To determine whether the K311 ubiquitina-
tion site is a target of MDM2 we mutated this site to argi-
nine. Firstly, we assessed the ability of K311R AR to in-
teract with MDM2 and we found that this interaction was
similar between WT AR and mutant K311R AR (Figure
2A). Additionally, MDM2 was able to efficiently ubiquiti-
nate AR lacking this site confirming that although K311
AR can be targeted by MDM2 it is not the sole target
site ofMDM2-mediated ubiquitination (Figure 2B). This is
supported by additional in vitro ubiquitination experiments
with MDM2 and a carboxy-terminal AR construct com-
prising bothDNAbinding domain (DBD) and ligand bind-
ing domain (LBD) which demonstrated a strong ubiquiti-
nation of this C-terminal construct byMDM2 (Figure 2C).
We have not yet been able to verify the C-terminal site(s) of
ubiquitination by MDM2 using MSMS.
K311 ubiquitination plays a role in AR protein stability and
is critical for its transcriptional activity
To determine whether the K311 ubiquitination site con-
tributed toward AR protein turnover we assessed AR pro-
tein stability in the LNCaP cells stably overexpressing a
lentiviral ARWT or ARK311R constructs by subjecting them
to cycloheximide treatment. Relative to p53 which demon-
strated the expected similar rapid turnover in both LNCaP
derivative cell lines, the wildtype AR had an approximate
half-life of 6 h whereas the AR K311R half-life was ex-
tended beyond 8 h (Figure 3A). This indicated that theK311
site is important for ubiquitination mediated AR protein
turnover. To test the importance of the K311 ubiquitination
site for AR transcriptional activity we created a lentiviral
expression model of WT and K311R AR. We used siRNA
targeting the endogenous 3′ UTR sequence ofAR (absent in
both exogenously overexpressed WT and K311R AR con-
structs), to ensure endogenous AR silencing (Figure 3B,
lanes 1 and 2). Subsequently we used LNCaP cells stably
overexpressing theWT or K311RAR lentiviral vectors and
silenced their endogenous AR using the siUTR sequence
(Figure 3B, lanes 3 and 4). Using this model we compared
androgen driven gene expression in LNCaP cells (lanes 3
and 4 of Figure 3B). We observed that even though, we had
higher levels of K311R AR protein compared to WT AR
(Figure 3B), due to increased protein stability (Figure 3A),
this mutant failed to effectively induce transcription of AR
target genes in the androgen dependent LNCaP cells indi-
cating the critical importance of K311 for AR transcrip-
tional activity (Figure 3C). To determine the reasons be-
hind the lack of transcriptional activity of the K311R AR
we assessed its ability to bind to AR co-factors. In the ab-
sence of androgen K311R had a very similar binding pat-
tern to WT AR however, upon the addition of androgen,
binding to both p300 and HSP90 was abrogated (Figure
3D).HSP90 is responsible for controllingAR stability in the
cytoplasm (29) whereas p300 was previously shown to be re-
quired for both androgen dependent and independent AR
activation. p300 is not only crucial for AR activation but
is also required for AR polyubiquitination and degradation
(30). Lack of K311R AR binding to p300 in the presence
of androgen is the likely cause of increased K311R AR sta-
bility coupled with lack of transcriptional activity. This was
further confirmed by a gene expression assay where tran-
scriptional activity of WT AR was significantly enhanced
by the addition of p300 while it had no effect on the activity
of K311R AR (Figure 3E).
AR protein lacking the K311 ubiquitination site is transcrip-
tionally inactive due to its chromatin retention
To determine why K311R AR is not efficient at activating
AR target gene transcription in response to androgen stim-
ulation we performed a PSA ‘walking’ ChIP experiment to
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Figure 1. In vitro identification ofK311 as a site of ARubiquitination. (A) In vitromonoubiquitination ofARbyMDM2upon addition ofATP.Monoubiq-
uitinated AR (AR-Ub1) was excised from the colloidal-coomassie stained gel forMSMS analysis. (B) Monoubiquitination of AR-NTD protein (AR-Ub1)
can be detected by Western blotting following in vitro ubiquitination reactions in the presence of ATP, UBE1, UBCH5 and UbK0 using four different E3
ligases; MDM2, hPIRH2, CHIP and E6AP. (C) MSMS spectrum of the tryptic peptide, <302>STEDTAEYSPFK*GGYTK<318>, observed following
in gel tryptic digest. Analysis of the spectrum locates unequivocally a diglycine modification to K311. (D) AR domain structure highlighting the novel site
of AR ubiquitination, K311, within the N-terminal domain (NTD). Previously identified RNF6 target lysines within the ligand binding domain (LBD)
are also indicated, K845 and K847. DBD––DNA binding domain, H––hinge.
Figure 2. AR K311 is not the sole target of MDM2-mediated ubiquitination. (A) HEK293T cells were transfected as indicated and AR with interacting
partners were immunoprecipitated followed by immunoblotting. (B) HEK293T cells were transfected as indicated followed by denaturing immunopre-
cipitation and immunoblotting. (C) Western blotting of AR DBD/H/LBD with annotated monoubiquitination (AR-Ub1) and di-monoubiquitination
(AR-diUb1) by MDM2 following in vitro ubiquitination assay. Reactions contained UBE1, UBE2D3, and UbK0 in the absence or presence of ATP to
activate the ubiquitination reaction.
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Figure 3. K311 is important for AR protein stability and plays a critical role for its transcriptional activity. (A) LNCaP cells stably expressing either
FLAG-WTAR or FLAG-ARK311R were subjected to treatment with 10 g/ml cycloheximide (CHX) as indicated, followed byWestern blotting with an
anti-FLAG antibody. Band intensity was quantified and graph represents three independent experiments ± SEM. (B) Silencing of endogenous AR using
siRNA targeting the 3′ UTR (siUTR) sequence absent in exogenous AR carrying vectors causes reduction in AR protein in non-transduced LNCaP cells
compared to scrambled control siRNA (siScr). Cells overexpressing lentiviral WT AR or AR K311R show increased levels of exogenous AR compared to
non-transduced LNCaP cells after silencing their endogenous AR with siUTR treatment. (C) qRT-PCR analysis of AR target gene expression in LNCaP
cells stably overexpressing WT or K311R AR after silencing endogenous AR. Cells were cultured in steroid depleted media for 72 h followed by 24h
treatment with 10 nM DHT. Data is a mean of three independent experiments normalized to HPRT1 ± SEM. (D) AR was immunoprecipitated from the
LNCaP cells stably overexpressing WT or K311R AR cultured in the presence or absence of 10 nM DHT followed by immunoblotting. (E) HEK293T
cells were transfected with WT or AR K311R alongside a luciferase reporter plasmid under the control of an androgen response sequence (ARE3) of the
PSA promoter with and without p300 overexpression. Cells were cultured in steroid depleted media for 48 hours before 24 h treatment ± 10 nM DHT.
Data represent a mean of three independent experiments ± SEM. Luciferase activity was normalized to each AR alone.
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Figure 4. K311R AR is retained on chromatin resulting in decreased transcriptional activity. (A) ChIP analysis of AR recruitment to the different regions
of the PSA gene, (B) promoter of TMPRSS2 and (C) promoter of KLK2 after androgen stimulation in LNCaP cells stably overexpressing WT or K311R
AR after silencing endogenous AR following 120 min 10 nMDHT stimulation. Data is a mean of three independent experiments± SEM. (D) LNCaP cells
expressing WT or K311R AR were cultured in steroid depleted media for 70 h followed by 2 h treatment with 10 nM DHT and AR cellular localization
was visualized by immunofluorescence.
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Figure 5. Mutation of Lysine 311 causes global changes to the LNCaP transcriptome. (A) RNA was sequenced in triplicate from LNCaP cells expressing
WT or K311R AR and genes most significantly deregulated in the presence of DHT were plotted. (B) RNA was sequenced in triplicate from LNCaP cells
expressing WT or K311R AR and genes most significantly deregulated in the absence of DHT were plotted. (C-D) Venn diagram of genes up- (C) and
down- (D) regulated in K311R expressing LNCaP cells compared to WT AR expressing cells. (E) Table of metabolic pathways most significantly affected
by mutation in K311 of the androgen receptor.
track its progress on chromatin. Wild type AR is recruited
to the PSA target gene at a promoter region in response to
androgen stimulation at 120 min, which is the optimal time
point for AR recruitment (data not shown), and is absent in
all the other regions of the gene. However, K311RAR levels
at the promoter region are not changed as much in response
to androgen stimulation and most importantly this mutant
is retained throughout the whole PSA gene in response to
androgen stimulation suggesting failure to effectively serve
its function as a transcription factor (Figure 4A). Similar
effects were observed for the TMPRSS2 (Figure 4B) and
KLK2 (Figure 4C) genes. In agreement with the ChIP data
when we analyzed the cellular distribution of AR we noted
that K311R had a higher nuclear presence in the absence
of androgen than the WT AR consequently the difference
between the K311R AR nuclear levels in the presence and
absence of AR was a lot less pronounced than observed for
the WT AR (Figure 4D).
Mutating lysine 311 of the AR causes global changes to the
cellular transcriptome
To analyse the effects of lysine 311mutation on PC cell tran-
scriptome we sequenced total RNA from WT and K311R
ARexpressingLNCaP cells.MutatingK311 had a dramatic
effect on the cellular transcriptome with 1036 genes signif-
icantly altered (adj. p value < 0.05) by at least 2-fold In
the presence of androgen and 771 in steroid depleted con-
ditions when compared to cells expressing WT AR. Most
significantly altered genes includedKLK3 (PSA) andKLK2
(Figure 5A and B). 44% of the genes downregulated by the
lack of K311 were common between both conditions whilst
this was the case for only 29% of significantly upregulated
genes (Figure 5C and D). GO term (biological process) en-
richment analysis revealed deregulation of genes in multi-
ple biological processes (Supplementary Figure S1). Most
significant changes were observed for chromatin organiza-
tion with K311 mutation causing an increase in the expres-
sion of the genes from this biological process in both the ab-
sence and presence of androgen (Figure 6). This is in agree-
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Figure 6. Mutation of K311 significantly upregulated the expression of
genes responsible for chromatin organization. Genes significantly dereg-
ulated by K311 mutation in AR were clustered into the respective biologi-
cal processes using Go term and a clustered heat map of genes involved in
chromatin organization was generated.
ment with the increased nuclear presence (Figure 4D) and
chromatin retention observed with K311RAR (Figure 4A–
C). Similarly cell adhesion andmotility, signal transduction
and developmental pathways were all affected by mutating
K311 highlighting the crucial role of this ubiquitination site
for AR activity (Supplementary Figures S2–S5).
Additionally, pathway enrichment analysis revealed that
abrogation of K311 ubiquitination site significantly af-
fects cellular metabolism with ascorbate and aldarate
metabolism significantly altered in both the presence and
absence of androgens. Furthermore, arginine and proline
metabolism (Supplementary Figure S6), steroid biosynthe-
sis (Supplementary Figure S7) and pentose and glucoro-
nate interconversions were affected in the presence of an-
drogen (Figure 5E). Mutating K311 also caused a signif-
icant increase in the drug metabolism pathway. Andro-
gen receptor activity has previously been linked to argi-
nine metabolism with AR interacting with protein arginine
methyltransferase 10 (PRMT10) (31), similarly PRTM6was
reported to co-activate the AR (32), conversely AR defi-
ciency alters the arginine-vasopressin sexually dimorphic
system (33).
C-terminal domain of AR is required for efficient ubiquitina-
tion in cells
To assess the importance ofK311 for total cellularARubiq-
uitination we first overexpressed the N-terminal domain
(NTD) of AR, however we failed to detect any ubiquiti-
nation of this domain by MDM2, in contrast to efficient
ubiquitination of full length AR (Figure 7A, left panel).
We repeated this experiment with extended AR NTD con-
structs that also included theDNAbinding domain (DBD),
NTD/DBD (Figure 7A, centre panel) and hinge (H) do-
main, NTD/DBD/H (Figure 7A, right panel), however we
consistently were unable to demonstrate any ubiquitination
of these variants in the cells even though we have previ-
ously shown that they can be successfully ubiquitinated in
vitro (Figure 1). This observation is potentially of high clin-
ical importance as in advanced, CRPC stage of disease it
is common to see the emergence of AR truncated variants
expression that lack the C-terminal ligand binding domain
(34). Consequently, these variants do not require androgen
to translocate to the nucleus as they lack the LBD but are
constitutively active. To determine if our observation with
AR domain deletion variants was clinically relevant we re-
peated this experiment using the AR-V7 and AR/1/2/3b
variants reported in the clinic. In agreement with our pre-
vious experiment we were not able to ubiquitinate these
variants within cells (Figure 7B). To confirm whether this
is also true when variants are endogenously expressed we
compared two prostate cancer cell lines, LNCaP cells rep-
resenting androgen sensitive early disease that express only
the full lengthARandCWR22Rv1 cells expressing both full
length AR and AR-Vs. We compared the levels of total AR
ubiquitination and also ubiquitination after silencing full
lengthARonly. InLNCaP cells, silencing full lengthARab-
rogated AR ubiquitination as predicted because these cells
only contain full length AR protein (Figure 7C). Interest-
ingly, in CWR22Rv1 cells when we silenced only the full
length AR we were not able to detect any ubiquitination of
the AR-V even though we used anN-terminal AR antibody
that will detect all AR-Vs. To ensure that this was not due
to the fact that our denaturing immunoprecipitation proto-
col was biased toward proteins in the cytoplasmic compart-
ment where unliganded full length ARmay be present when
AR-Vs reside on chromatin, we repeated the CWR22Rv1
experiments but we first performed cytoplasmic and chro-
matin extractions and denaturing IP was performed from
each fraction.Using aC-terminal antibody that targets only
the full length AR we could detect ubiquitinated full length
AR in both the cytoplasmic and chromatin fractions, how-
ever even though AR-V7 protein was present on chromatin
no ubiquitination of the AR-V7 variant was observed (Fig-
ure 7D). This indicated that even though K311 is an AR
ubiquitination site, the LBD is essential for either the cor-
rect folding that allows substrate recognition by the E2/E3
or that the recognition site for E3 ligase binding AR is
within the LBD, as ubiquitination frequently occurs in a re-
gion that is distinct from the substrate recognition site. To
confirm our observation we compared the transcriptional
activity of FLAR and truncatedN-terminal ARs both with
and without the functional K311 site. We observed that all
of theN-terminal AR variant constructs were constitutively
active and their activity was not affected by androgen stim-
ulation, similarly their activity, unlike that of the full length
AR, was not altered by lack of functionalK311 (Figure 7E).
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Figure 7. Truncated AR variants are not ubiquitinated. (A-B) Cells were transfected with plasmids as indicated followed by denaturing immunoprecipita-
tion and western blotting. (C) LNCaP and CWR22Rv1 cells were treated with siRNAs as indicated for 96 h followed by denaturing immunoprecipitation
and immunoblotting. (D) Chromatin and cytoplasm fractions were isolated from the CWR22Rv1 cells and denaturing immunoprecipitation was performed
on each cellular fraction followed by immunoblotting. (E) HEK293T cells were transfected with WT AR or AR K311R along with a luciferase reporter
plasmid under the control of ARE3 of the PSA promoter. Cells were cultured in steroid depleted media for 48 h before 24 h treatment ± 10 nM DHT.
Data represent a mean of three independent experiments ± SEM. Luciferase activity was normalized to WT AR + DHT.
DISCUSSION
As a key driver of PC the AR is the main therapeutic tar-
get in both early and advanced disease. However, treatments
targeting the AR invariably fail and result in the develop-
ment of CRPC. There are multiple mechanisms through
which PC can acquire the CRPC phenotype, these include
AR mutations, AR amplification and generation of AR
splice variants. In addition, intracrine androgen synthesis
can occur in prostate tumours and aberrant activation of
alternative signaling pathways can also activate theAR. Im-
portantly, the AR is still expressed and it continues to be a
driver in CRPC and therefore it remains a viable therapeu-
tic target (35). As such, understandingmechanisms through
which AR protein activity and stability is controlled could
help us identify novel therapeutic targets.
It has been previously established that AR activity and
protein stability is regulated by the ubiquitin proteasome
system. Previously two AR ubiquitination sites in the AF2
region of the LBD have been reported at K845 and K847.
Both sites are targeted by RNF6 with K845 ubiquitination
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required for K847 ubiquitination and for ARA54 recruit-
ment (11). Ubiquitination occurring at either of these sites
is linked to AR transcriptional activity but is not associated
with AR protein turnover. MDM2 was the first E3 identi-
fied to target AR, ubiquitination of AR by MDM2 being
dependent on AR phosphorylation at S515 by CDK7 ki-
nase via TFIIH. Additionally, MDM2 needs to be phos-
phorylated at S166 by AKT highlighting the complexity of
the E3-substrate interaction. If AR S515 is not phosphory-
lated then the AR is alternatively targeted for proteasomal
degradation by CHIP.
Herein we report the identification of a novel AR ubiq-
uitination site in the N-terminal domain at position 311.
The ubiquitination of lysine 311 affects AR protein stability
however, its critical role appears to be in regulatingAR tran-
scriptional activity and chromatin retention. When K311
is mutated to arginine, the stability of the AR protein is
increased. Similarly, mutated AR that cannot be ubiquiti-
nated at the K311 site has dramatically reduced transcrip-
tional activity toward androgen responsive AR target genes
with global LNCaP transcriptome significantly altered and
cellular metabolism pathways, including drug metabolism
affected, highlighting the important role that lysine 311
plays in AR signaling. We further observe enhanced levels
of K311R AR on chromatin throughout the whole andro-
gen responsive PSA gene. We suggest this may be a conse-
quence of defective AR cycling on and off the chromatin
in response to androgen stimulation possibly because of the
inability ofK311RAR to bind to p300 in the presence of an-
drogen highlighted by the increase in the expression of genes
responsible for chromatin organization upon K311 muta-
tion. We also report that AR variants that lack the LBD,
including the clinically relevant AR-V7, cannot be ubiqui-
tinated within the cell demonstrating the crucial contribu-
tion of AR LBD for E2/E3 complex binding and substrate
recognition. It has been previously reported that E3 ligase
binding can be affected by the presence of additional fac-
tors, Siah2 can ubiquitinate AR only when it is bound to
NCOR-1 and transcriptionally inactive, this ubiquitination
consequently targets AR for degradation (36). Additionally,
in some cases AR needs a mediator protein to be recruited
to the E3s. For AR ubiquitination by NEDD4, PMEPA1
recruits AR resulting in its ubiquitination and subsequent
degradation (37). It is possible that there is a mediator pro-
tein that allows for E3 recruitment to AR that is bound in
the LBD and facilitates the N-terminal ubiquitination at
K311.
Mutation at K311 has not been reported in RNA-
seq of PC patients (COSMIC). However, in the PC346
model derived from a primary human prostate tumour
subcutaneously implanted into athymic mice that were
subsequently castrated, an androgen-independent subline,
PC346DCC emerged that contained the K311R AR muta-
tion (38). Interestingly, PC346DCC cell line exhibits rapid
proliferation in steroid deprived media and is unresponsive
to either R1881 or OH-flutamide (39).
AR phosphorylation of serine 308 (S308), adjacent to
K311, is associated with a longer time to disease specific
death (40) and may impact ubiquitination at the K311
residue. Our preliminary experiments however in mutating
S308 to alanine failed to impact on AR transcriptional ac-
tivity in luciferase reporter assays (data not shown).
Potentially, the role of the LBD in K311 AR ubiquitina-
tion could be important if ubiquitination occurred mainly
outside of the nucleus as the LBD contains a nuclear export
signal (NES) which has been previously reported to signal
for poly-ubiquitination and degradation but it is blocked
by binding to androgens which inhibits NES (32). Conse-
quently, in the presence of androgens, AR half-life was re-
ported to increase in LNCaP cells from 3h to over 10h as a
result of NES inhibition. However, there must be an addi-
tional role for the LBD in AR recruitment to E3s as it has
been demonstrated thatMDM2 can ubiquitinate AR at tar-
get gene promoters (10). The role of MDM2-mediated AR
K311 ubiquitination occurring on chromatin may therefore
function to promote AR chromatin dissociation and the
subsequent recycling of AR to induce new rounds of an-
drogen responsive gene transcriptional activity.
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